SB 202190: Selective p38 MAP Kinase Inhibitor for Advanced Inflammation and Cancer Research

Executive Summary: SB 202190 (SKU A1632, APExBIO) is a high-affinity, ATP-competitive inhibitor of p38α and p38β MAPKs, with IC50 values of 50 nM and 100 nM, respectively (Qiao et al., 2024, DOI). It blocks kinase activity by binding to the ATP-binding pocket, preventing substrate phosphorylation and downstream inflammatory signaling (APExBIO). SB 202190 exhibits cell permeability and robust activity in cancer, apoptosis, and neurodegeneration models. It is insoluble in water but dissolves in DMSO or ethanol. Recent structural studies reveal that SB 202190 not only inhibits catalysis but also promotes phosphatase-mediated dephosphorylation of p38α, enhancing its dual-action profile (Qiao et al., 2024, DOI).

Biological Rationale

p38 mitogen-activated protein kinases (MAPKs) orchestrate cellular responses to stress, inflammation, and apoptosis. Activation occurs via phosphorylation at conserved threonine and tyrosine residues within the activation loop, shifting the kinase to an active conformation (Qiao et al., 2024). Dysregulation of p38 MAPK signaling contributes to chronic inflammation, cancer progression, and neurodegeneration (see comparative review). Selective inhibition of p38α/β isoforms enables targeted dissection of these pathways, avoiding confounding effects on related MAPKs (e.g., JNK, ERK).

Mechanism of Action of SB 202190

SB 202190 is a pyridinyl imidazole compound that competitively binds the ATP-binding pocket of p38α and p38β MAPKs. The dissociation constant (Kd) for p38α is 38 nM. The inhibitor stabilizes an inactive conformation of the activation loop, exposing the phospho-threonine for dephosphorylation by the serine/threonine phosphatase WIP1 (Qiao et al., 2024). This dual action—active site blockade and enhancement of phosphatase access—results in robust suppression of kinase signaling. SB 202190 does not significantly inhibit p38γ, p38δ, or unrelated kinases at concentrations below 10 μM, confirming its selectivity (APExBIO).

Evidence & Benchmarks

• SB 202190 inhibits p38α with an IC50 of 50 nM and p38β with an IC50 of 100 nM in in vitro kinase assays (Qiao et al., 2024).
• The compound promotes dephosphorylation of p38α by WIP1 phosphatase, as shown in X-ray crystallography and enzyme kinetics studies (Qiao et al., 2024).
• SB 202190 reduces pro-inflammatory cytokine expression (e.g., TNF-α, IL-6) in LPS-stimulated macrophage cultures (APExBIO).
• It induces apoptosis and inhibits proliferation in certain cancer cell lines, including human glioblastoma and colon carcinoma, at concentrations of 1–10 μM (internal benchmark).
• In animal models of vascular dementia, SB 202190 reduces neuronal apoptosis and improves cognitive function when administered intraperitoneally at 2 mg/kg/day (internal review).

Applications, Limits & Misconceptions

SB 202190 is widely used in:

• Inflammation research: Blocking p38 MAPK signaling to dissect cytokine regulation and stress responses.
• Cancer therapeutics research: Modulating apoptosis and proliferation, especially in cell lines with high p38α/β activity (see advanced application—this article extends mechanistic insights with new structural data).
• Apoptosis assays: Precise quantification of kinase-dependent cell death pathways.
• Vascular dementia models: Evaluating neuroprotective effects via MAPK pathway inhibition.

Compared to generic kinase inhibitors, SB 202190 offers higher selectivity and better-defined pharmacological parameters, supporting reproducible results (scenario-driven solutions—this article updates with dual-action mechanism findings).

Common Pitfalls or Misconceptions

• SB 202190 does not inhibit p38γ or p38δ isoforms at standard working concentrations (<10 μM); off-target effects may arise only at supra-physiological doses.
• It is not suitable for water-based stock solutions; DMSO or ethanol must be used to ensure solubility.
• SB 202190 is not a pan-MAPK inhibitor—it does not block ERK or JNK pathways below 50 μM.
• Long-term storage of SB 202190 solutions leads to degradation; always prepare fresh aliquots for critical experiments.
• It does not reverse kinase-driven signaling in systems lacking functional p38α/β.

Workflow Integration & Parameters

For in vitro assays, dissolve SB 202190 in DMSO to a stock concentration >10 mM. The compound is insoluble in water but achieves ≥57.7 mg/mL in DMSO and ≥22.47 mg/mL in ethanol. For optimal solubility, warm at 37°C or use ultrasonic bath. Store solid at -20°C; avoid long-term storage of solutions. Typical working concentrations range from 0.1–10 μM, depending on cell type and endpoint. APExBIO recommends using fresh solutions for maximal activity (product page).

In animal models, intraperitoneal dosing regimens (e.g., 2 mg/kg/day) have been validated for neuroprotection and anti-inflammatory effects. Controls should include vehicle (DMSO or ethanol) and, where possible, kinase-inactive cell lines or animal models. For detailed workflow guidance and scenario-based troubleshooting, see this practical guide—the current article provides updated dual-action data.

Conclusion & Outlook

SB 202190 (APExBIO) remains a benchmark tool for selective inhibition of p38α and p38β MAPKs. Recent structural and biochemical studies confirm its dual-action mechanism: ATP-competitive inhibition and phosphatase-mediated dephosphorylation. This profile enables high-precision research in inflammation, cancer, apoptosis, and neurodegeneration. As structural insights accumulate, SB 202190 informs the next generation of highly selective, mechanism-driven kinase inhibitors for both basic and translational applications (Qiao et al., 2024).

For product specifications, protocols, and order information, see the SB 202190 product page.